Azukaitis Karolis, Simkova Eva, Majid Mohammad Abdul, Galiano Matthias, Benz Kerstin, Amann Kerstin, Bockmeyer Clemens, Gajjar Radha, Meyers Kevin E, Cheong Hae Il, Lange-Sperandio Bärbel, Jungraithmayr Therese, Frémeaux-Bacchi Véronique, Bergmann Carsten, Bereczki Csaba, Miklaszewska Monika, Csuka Dorottya, Prohászka Zoltán, Killen Paul, Gipson Patrick, Sampson Matthew G, Lemaire Mathieu, Schaefer Franz
Clinic of Pediatrics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania;
Pediatric Nephrology Department, Dubai Hospital, Dubai, United Arab Emirates.
J Am Soc Nephrol. 2017 Oct;28(10):3066-3075. doi: 10.1681/ASN.2017010031. Epub 2017 May 19.
The recent discovery of mutations in the gene encoding diacylglycerol kinase (DGKE) identified a novel pathophysiologic mechanism leading to HUS and/or MPGN. We report ten new patients from eight unrelated kindreds with DGKE nephropathy. We combined these cases with all previously published cases to characterize the phenotypic spectrum and outcomes of this new disease entity. Most patients presented with HUS accompanied by proteinuria, whereas a subset of patients exhibited clinical and histologic patterns of MPGN without TMA. We also report the first two patients with clinical and histologic HUS/MPGN overlap. DGKE-HUS typically manifested in the first year of life but was not exclusively limited to infancy, and viral triggers frequently preceded HUS episodes. We observed signs of complement activation in some patients with DGKE-HUS, but the role of complement activation remains unclear. Most patients developed a slowly progressive proteinuric nephropathy: 80% of patients did not have ESRD within 10 years of diagnosis. Many patients experienced HUS remission without specific treatment, and a few patients experienced HUS recurrence despite complete suppression of the complement pathway. Five patients received renal allografts, with no post-transplant recurrence reported. In conclusion, we did not observe a clear genotype-phenotype correlation in patients with DGKE nephropathy, suggesting additional factors mediating phenotypic heterogeneity. Furthermore, the benefits of anti-complement therapy are questionable but renal transplant may be a feasible option in the treatment of patients with this condition.
最近在编码二酰基甘油激酶(DGKE)的基因中发现的突变,确定了一种导致溶血尿毒综合征(HUS)和/或膜增生性肾小球肾炎(MPGN)的新病理生理机制。我们报告了来自8个无关家族的10例DGKE肾病新患者。我们将这些病例与之前所有已发表的病例相结合,以描述这种新疾病实体的表型谱和预后。大多数患者表现为伴有蛋白尿的HUS,而一部分患者表现出无血栓性微血管病(TMA)的MPGN临床和组织学模式。我们还报告了首例临床和组织学表现为HUS/MPGN重叠的2例患者。DGKE-HUS通常在生命的第一年出现,但并不局限于婴儿期,且HUS发作前常由病毒触发。我们在一些DGKE-HUS患者中观察到补体激活的迹象,但补体激活的作用仍不清楚。大多数患者发展为缓慢进展的蛋白尿性肾病:80%的患者在诊断后10年内未发展为终末期肾病(ESRD)。许多患者未经特殊治疗HUS缓解,少数患者尽管补体途径被完全抑制仍出现HUS复发。5例患者接受了肾移植,未报告移植后复发。总之,我们在DGKE肾病患者中未观察到明确的基因型-表型相关性,提示存在其他介导表型异质性的因素。此外,抗补体治疗的益处尚不确定,但肾移植可能是治疗该疾病患者的一个可行选择。